Imaging agents:

Indications for: OXILAN

Intraarterial: For cerebral arteriography (300mgI/mL). For coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography (350mgI/mL). IV: For excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300mgI/mL and 350mgI/mL).

Adult Dosage:

Individualize. Intraarterial procedures: Left and right coronary: 2–10mL. Left ventricle: 25–50mL. Aortography and selective visceral: see literature. Aortic bifurcation for distal runoff: 45–100mL. Subclavian or femoral artery: 10–40mL. Total dose for procedure should not exceed 250mL. Cerebral arteriography: 8–12mL; total dose for procedure should not exceed 150mL. IV procedures: Excretory urography: 250–390mgI/kg; total dose for procedure should not exceed 100mL. CECT of the head: 100–200mL (300mgI/mL) or 86–172mL (350mgI/mL); total dose for procedure should not exceed 200mL. CECT of body: 50–200mL (300mgI/mL) or 43–172mL (350mgI/mL); total dose for procedure should not exceed 200mL.

Children Dosage:

Not recommended.

OXILAN Contraindications:

Intrathecal use.

OXILAN Warnings/Precautions:

Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune disorders. Maintain adequate hydration. History of sever cutaneous hypersensitivity reaction; avoid. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

OXILAN Classification:

Nonionic contrast agent.

OXILAN Interactions:

Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.

Adverse Reactions:

Headache, fever, hematoma at inj site, chills, angina, hypertension, bradycardia, hypotension, GI upset, dizziness, urticaria, rash; thromboembolic events, hypersensitivity reactions, severe cutaneous reactions (eg, SJS/TEN, AGEP, DRESS).

How Supplied:

Single-dose bottles (50mL, 100mL, 150mL, 200mL)—10